Advertisement

International Urogynecology Journal

, Volume 24, Issue 4, pp 683–688 | Cite as

Effects of propiverine hydrochloride, an anticholinergic agent, on urethral continence mechanisms and plasma catecholamine concentration in rats

  • Takeya Kitta
  • Vikas Tyagi
  • Masato Nanri
  • Mamoru Kiniwa
  • Katsuya Nonomura
  • Naoki YoshimuraEmail author
Original Article

Abstract

Introduction and hypothesis

Anticholinergics are used to treat overactive bladder. Anticholinergic agents such as propiverine hydrochloride reportedly increase plasma catecholamine levels in rats. It is also known that active urethral closure mechanisms prevents stress urinary incontinence (SUI), which is enhanced by central and peripheral noradrenergic system activation. Therefore, we examined the influence of propiverine hydrochloride on urethral anti-incontinence function in rats.

Methods

Adult female rats were divided into propiverine and vehicle-treated groups. The propiverine group was given propiverine orally once a day for 2 weeks, after which urethral function and plasma concentrations of catecholamine (dopamine, norepinephrine, epinephrine) were tested.

Results

Urethral baseline pressure measured by a microtransducer-tipped urethral catheter and leak-point pressure during passive intravesical pressure elevation were significantly increased in the propiverine group compared with the vehicle group. Plasma norepinephrine and epinephrine levels in the propiverine group were also significantly increased.

Conclusions

Propiverine treatment that increases plasma catecholamine levels could contribute to improvement of SUI conditions by increasing urethral resistance.

Keywords

Stress urinary incontinence Anticholinergic agent Propiverine hydrochloride Rat 

Abbreviation

SUI

Stress urinary incontinence

A-URS

Amplitude of urethral responses during sneezing

UBP

Urethral baseline pressure

LPP

Leak-point pressure

MUI

Mixed urinary incontinence

Notes

Conflicts of interest

M Nanri and M Kiniwa are both employees of TAIHO Phamaceutical Co.

References

  1. 1.
    Khullar V, Chapple C, Gabriel Z, Dooley JA (2006) The effects of antimuscarinics on health-related quality of life in overactive bladder: a systematic review and meta-analysis. Urology 68:38–48PubMedCrossRefGoogle Scholar
  2. 2.
    Nishijima S, Sugaya K, Kadekawa K, Naka H, Miyazato M (2009) Comparison of the effect of anti-muscarinic agents on bladder activity, urinary ATP level, and autonomic nervous system in rats. Biomed Res 30:107–112PubMedCrossRefGoogle Scholar
  3. 3.
    Nishijima S, Sugaya K, Kadekawa K, Ashitomi K, Yamamoto H (2011) Efficacy of propiverine, an anticholinergic agent, in young and old rats. Life Sci 89:456–459PubMedCrossRefGoogle Scholar
  4. 4.
    Kamo I, Torimoto K, Chancellor MB, de Groat WC, Yoshimura N (2003) Urethral closure mechanisms under sneeze-induced stress condition in rats: a new animal model for evaluation of stress urinary incontinence. Am J Physiol Regul Integr Comp Physiol 285:R356–R365PubMedGoogle Scholar
  5. 5.
    Kamo I, Cannon TW, Conway DA et al (2004) The role of bladder-to-urethral reflexes in urinary continence mechanisms in rats. Am J Physiol Renal Physiol 287:F434–F441PubMedCrossRefGoogle Scholar
  6. 6.
    Kaiho Y, Kamo I, Chancellor MB, Arai Y, de Groat WC, Yoshimura N (2007) Role of noradrenergic pathways in sneeze-induced urethral continence reflex in rats. Am J Physiol Renal Physiol 292:F639–F646PubMedCrossRefGoogle Scholar
  7. 7.
    Miyazato M, Kaiho Y, Kamo I et al (2008) Effect of duloxetine, a norepinephrine and serotonin reuptake inhibitor, on sneeze-induced urethral continence reflex in rats. Am J Physiol Renal Physiol 295:F264–F271PubMedCrossRefGoogle Scholar
  8. 8.
    Lee JY, Cannon TW, Pruchnic R, Fraser MO, Huard J, Chancellor MB (2003) The effects of periurethral muscle-derived stem cell injection on leak point pressure in a rat model of stress urinary incontinence. Int Urogynecol J Pelvic Floor Dysfunct 14:31–37PubMedCrossRefGoogle Scholar
  9. 9.
    de Groat WC, Fraser MO, Yoshiyama M et al (2001) Neural control of the urethra. Scand J Urol Nephrol Suppl 207:35–43PubMedCrossRefGoogle Scholar
  10. 10.
    Kadekawa K, Nishijima S, Ashitomi K et al (2012) Excitatory effect of propiverine hydrochloride on urethral activity in rats. Int J Urol 19:575–582PubMedCrossRefGoogle Scholar
  11. 11.
    Steers WD (2002) Overactive bladder (OAB): what we thought we knew. Eur Urol Suppl 1:3–10CrossRefGoogle Scholar
  12. 12.
    Andersson KE, Appell R, Cardozo L et al (2005) Pharmacological treatment of urinary incontinence. In: Andersson KE, Khoury S, Wein A (eds) Incontinence: 3rd International Consultation on Incontinence. Plymbridge Distributors, Plymouth, p 819Google Scholar
  13. 13.
    Madersbacher H, Murtz G (2001) Efficacy, tolerability and safety profile of propiverine in the treatment of the overactive bladder (non-neurogenic and neurogenic). World J Urol 19:324–335PubMedCrossRefGoogle Scholar
  14. 14.
    Kreder KJ Jr, Brubaker L, Mainprize T (2003) Tolterodine is equally effective in patients with mixed incontinence and those with urge incontinence alone. BJU Int 92:418–421PubMedCrossRefGoogle Scholar
  15. 15.
    Dorschner W, Stolzenburg JU, Griebenow R et al (2000) Efficacy and cardiac safety of propiverine in elderly patients—a double-blind, placebo-controlled clinical study. Eur Urol 37:702–708PubMedCrossRefGoogle Scholar
  16. 16.
    Dorschner W, Stolzenburg JU, Griebenow R et al (2003) The elderly patient with urge incontinence or urge-stress incontinence—efficacy and cardiac safety of propiverine. Aktuelle Urol 34:102–108PubMedCrossRefGoogle Scholar

Copyright information

© The International Urogynecological Association 2012

Authors and Affiliations

  • Takeya Kitta
    • 1
    • 2
  • Vikas Tyagi
    • 1
  • Masato Nanri
    • 3
  • Mamoru Kiniwa
    • 3
  • Katsuya Nonomura
    • 2
  • Naoki Yoshimura
    • 1
    Email author
  1. 1.Department of UrologyUniversity of Pittsburgh School of MedicinePittsburghUSA
  2. 2.Department of Renal and Genitourinary Surgery, Graduate School of MedicineHokkaido UniversitySapporoJapan
  3. 3.TAIHO Phamaceutical Co., Ltd.TokyoJapan

Personalised recommendations